Quantifying the impact of interventions against <em>Plasmodium vivax</em>: a model for country-specific use (Publications)
fictitious data, by simulating and comparing the impact of various intervention combinations on malaria risk and burden, this model could be a useful tool for strategic planning, implementation and resource
Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design (Publications)
anticipated use of the intervention in target countries. Examples are provided from research on malaria vaccines that are also applicable to other new public health interventions
Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning (Publications)
available to treat diseases such as leishmaniasis, Chagas' disease, human African trypanosomiasis and malaria. Since drug development is lengthy and expensive, a drug repurposing strategy offers an attractive
Using observed incidence to calibrate the transmission level of a mathematical model for <em>Plasmodium vivax</em> dynamics including case management... (Publications)
model is used to calculate local reproduction numbers in Panama and identify areas of sustained malaria transmission that should be targeted by control interventions.
Estimation of the antirelapse efficacy of tafenoquine, using <em>Plasmodium vivax</em> genotyping (Publications)
Plasmodium vivax relapse prevention is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled Phase IIb study in Peru, India, Thailand
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents (Publications)
mice. The optimized compounds were found to be more efficacious than the current antimalarials in a malaria mouse model. They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient
Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning (Publications)
available to treat diseases such as leishmaniasis, Chagas' disease, human African trypanosomiasis and malaria. Since drug development is lengthy and expensive, a drug repurposing strategy offers an attractive
Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design (Publications)
anticipated use of the intervention in target countries. Examples are provided from research on malaria vaccines that are also applicable to other new public health interventions
Eric Huber (People)
https://www.swisstph.ch/en/staff/profile/people/eric-huber
monitoring of trials, mainly in resource-limited countries, focusing on neglected diseases such as malaria, tuberculosis and helminth infections. Through this work he has gained extensive experience in the
Osama Seidahmed (People)
https://www.swisstph.ch/en/staff/profile/people/osama-seidahmed
c region. His work includes diverse operational outcomes in the battle against diseases such as malaria, dengue, Chikungunya, and Rift Valley fever. He also contributed to the teaching at a college level
